In CML, we found that dasatinib-specific inhibition of p38 and GATA-3 transcriptional activities depleted NKG2A, leading to higher NK cytotoxicity and stronger anti-CML responses. The gene discussed is GATA3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.